SuperworthStoke Therapeutics revenue STOK
Sales by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- $27.6M
- Latest quarter, Q2 FY26
- $9.3M
- −33% on a year earlier
- Fiscal year 2025
- $184.4M
- +405% on the year before
Stoke Therapeutics' revenue was $27.6M over the twelve months to Jun 30, 2026, down 86% on a year earlier.
In its latest quarter, Q2 FY26, it was $9.3M, down 33% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $184.4M | +405% |
| FY2024 | $36.6M | +316% |
| FY2023 | $8.8M | −29% |
| FY2022 | $12.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $9.3M | −33% | $27.6M | |
| Q1 FY26 | $6.2M | −96% | $32.1M | |
| Q4 FY25 | $1.4M | −94% | $184.4M | |
| Q3 FY25 | $10.6M | +117% | $205.6M | |
| Q2 FY25 | $13.8M | +186% | $199.9M | |
| Q1 FY25 | $158.6M | +3661% | $190.9M | |
| Q4 FY24 | $22.6M | +707% | $36.6M | |
| Q3 FY24 | $4.9M | +48% | $16.7M | |
| Q2 FY24 | $4.8M | n/a | $15.2M | |
| Q1 FY24 | $4.2M | −18% | $7.8M | |
| Q4 FY23 | $2.8M | −14% | $8.8M | |
| Q3 FY23 | $3.3M | +14% | $9.2M |
Against its peers
Companies in Drug Manufacturers - General nearest Stoke Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| STOKStoke Therapeutics | $27.6M | −86% a year |
| PAHCPhibro Animal Health | $1.5B | +17% a year |
| ANIPANI Pharmaceuticals | $978.4M | +31% a year |
| ANABAnaptysbio | n/m | |
| PCRXPacira BioSciences | $746.2M | +6% a year |
| HRMYHarmony Biosciences | $959.9M | +24% a year |
| OMEROmeros | n/m | |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| AMPHAmphastar Pharmaceuticals | $730M | +1% a year |
| NRIXNurix Therapeutics | $701.9M | |
| ABUSArbutus Biopharma | $181.7M | |
| Peer median | $853M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Stoke Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.